{"product_id":"veracyte-marketing-mix","title":"Veracyte Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic 4Ps Marketing Mix for Diagnostic Commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eVeracyte's 4Ps framework aligns product positioning, value-based pricing, targeted channel partnerships, and evidence-led promotion into a commercial strategy that supports clinician adoption and market access. Purchase the full, editable 4P's Marketing Mix Analysis for actionable product roadmaps, pricing models, distribution maps, and promotional templates tailored for presentations, benchmarking, and execution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Genomic Testing Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte's Comprehensive Genomic Testing Portfolio includes Afirma Thyroid FNA and Decipher Prostate, using whole-transcriptome sequencing to improve benign vs malignant calls and reduce unnecessary surgeries; Afirma adoption cut diagnostic surgeries by ~50% in published series.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 the portfolio added MRD testing and expanded lung cancer assays, positioning revenue diversification-Afirma and Decipher drove ~$340M revenue in 2024 and MRD\/lung aim to address $6-8B TAM across oncology and urology.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThe nCounter Analysis System\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte leverages the nCounter Analysis System as a decentralized, lab-deployable platform that combines hardware and software for high-throughput genomic signature analysis, avoiding central-hub shipping and cutting sample transit time by days; in 2025 the system supports over 200 global labs and contributes to a \u0026gt;25% faster turnaround versus centralized testing. It remains a strategic differentiator, driving access to advanced genomics and supporting recurring reagent revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Utility and Actionable Insights\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte products deliver clinically actionable insights that cut unnecessary surgeries and costs-Percepta Nasal Swab and Envisia Genomic Classifier together reduced invasive procedures by ~30% in published cohorts (2023-2025) and saved an estimated $2,400 per avoided surgery in payer-modeled analyses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopharmaceutical Services and Research Tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVeracyte's Biopharmaceutical Services and Research Tools offer genomic services-biomarker discovery and patient stratification-using its 500k+ genomic database and bioinformatics platform to support drug development and trials.\u003c\/p\u003e\n\u003cp\u003eThis product line generated ~12% of 2025 revenue (estimated $54M of $450M FY2025) and builds multi-year partnerships that feed trial data back into diagnostic R\u0026amp;D, accelerating new test launches.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e500k+ genomic profiles\u003c\/li\u003e\n\u003cli\u003e~$54M revenue (12% of FY2025)\u003c\/li\u003e\n\u003cli\u003eBiomarker discovery \u0026amp; stratification\u003c\/li\u003e\n\u003cli\u003eFeeds data to diagnostic pipeline\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and Bioinformatics Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVeracyte pairs its lab tests with digital health and bioinformatics platforms that deliver intuitive reports and visualizations, helping clinicians interpret genomic data and securely share findings across multi-disciplinary teams.\u003c\/p\u003e\n\u003cp\u003eSoftware updates incorporate latest clinical guidelines and therapeutic recommendations; in 2024 Veracyte reported digital-driven engagement rising 28% year-over-year, boosting test adoption and clinician retention.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eIntegrates lab results with dashboards for clinicians\u003c\/li\u003e\n\u003cli\u003eSecure team sharing and EHR compatibility\u003c\/li\u003e\n\u003cli\u003eRegular guideline-driven software updates\u003c\/li\u003e\n\u003cli\u003e2024 digital engagement +28%, improving adoption\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte: Diversified diagnostics fueling $450M 2025 growth - Afirma\/Decipher \u0026amp; MRD lead\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte's product mix: Afirma, Decipher, MRD\/lung assays, nCounter platform, Percepta\/Envisia, and biopharma services drive clinical impact and recurring revenue-Afirma\/Decipher ~$340M 2024; FY2025 revenue ~$450M (MRD\/lung growth target TAM $6-8B); biopharma $54M (12% FY2025); nCounter in 200+ labs, \u0026gt;25% faster TAT; digital engagement +28% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024-25\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAfirma\/Decipher\u003c\/td\u003e\n\u003ctd\u003e$340M (2024)\u003c\/td\u003e\n\u003ctd\u003e~50% fewer surgeries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiopharma\u003c\/td\u003e\n\u003ctd\u003e$54M (12% FY2025)\u003c\/td\u003e\n\u003ctd\u003e500k+ profiles\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003enCounter\u003c\/td\u003e\n\u003ctd\u003e200+ labs (2025)\u003c\/td\u003e\n\u003ctd\u003e25% faster TAT\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Veracyte's Product, Price, Place, and Promotion strategies-grounded in real practices and competitive context for managers, consultants, and marketers to benchmark and adapt.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSummarizes Veracyte's 4Ps in a concise, structured snapshot to relieve analysis burden, ideal for leadership briefings or rapid internal alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCentralized CLIA-Certified Laboratories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte runs CLIA-certified, CAP-accredited labs in South San Francisco and Austin that process most North American genomic sequencing; in 2024 these central labs supported ~85% of commercial test volume, helping produce $353M revenue company-wide. Centralization enforces uniform quality controls and data integrity, shortens validation cycles, and cut per-test operating cost by an estimated 12% versus decentralized models. This setup lets Veracyte scale new tests rapidly-launch-to-commercialization compressed to ~6-9 months for recent assays.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Decentralized Testing Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThrough the nCounter platform, Veracyte has built a global decentralized testing network enabling local labs in Europe and Asia to run assays, avoiding cross-border sample shipping and cutting logistics costs by an estimated 30%.\nBy enabling local processing, Veracyte meets regional legal preferences and has expanded market access, supporting revenue growth-company reported molecular diagnostics revenue rose ~18% in 2024.\nBy end-2025 the network covered dozens of top-tier academic and commercial labs worldwide, exceeding 40 partner sites and shortening turnaround time by ~2-5 days.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Biopharmaceutical Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte leverages strategic alliances with global pharmaceutical firms as a distribution channel for genomic insights, co-developing diagnostics that match patients to therapies; by Q4 2025 partnerships contributed to ~30% of test orders and drove $58M in collaboration revenue in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales and Specialist Outreach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVeracyte uses a specialized direct sales force targeting oncologists, urologists, and pulmonologists in high-volume centers and integrated delivery networks, focusing sales where diagnostic uncertainty is highest.\u003c\/p\u003e\n\u003cp\u003eReps embedded in clinics provide hands-on support and education, driving test adoption during consultations; Veracyte reported direct sales growth contributing to 2024 revenue of $372.6M, up 16% vs 2023.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets: oncology, urology, pulmonology clinics\u003c\/li\u003e\n\u003cli\u003eFocus: high-volume centers and IDNs\u003c\/li\u003e\n\u003cli\u003eMethod: in-clinic reps for education\/support\u003c\/li\u003e\n\u003cli\u003eImpact: increases test use at point-of-care; 2024 revenue $372.6M (+16%)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Distribution Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVeracyte uses experienced independent distributors where direct sales aren't feasible, giving local market know-how, regulatory navigation, and logistics support to enter diverse regions.\u003c\/p\u003e\n\u003cp\u003eThis distributor model cuts overhead versus local subsidiaries, letting Veracyte scale globally; by 2025 it helped launch the diagnostic portfolio in emerging markets with double-digit annual test volume growth in selected countries.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLower fixed costs vs. subsidiaries\u003c\/li\u003e\n\u003cli\u003eLocal regulatory expertise\u003c\/li\u003e\n\u003cli\u003eFaster market entry, higher scale\u003c\/li\u003e\n\u003cli\u003e2025: double-digit test growth in target markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte scales central labs, cuts costs, boosts revenue to $372.6M with partner growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte central labs (SSF, Austin) processed ~85% of NA volume in 2024, supporting $353M revenue and cutting per-test costs ~12%; decentralized nCounter partners (40+ sites by 2025) reduced logistics ~30% and TAT by 2-5 days, aiding ~18% molecular revenue growth in 2024. Pharma partnerships drove ~30% of orders and $58M collaboration revenue in 2024; direct sales and distributors pushed company-wide revenue to $372.6M (+16%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCentral lab share\u003c\/td\u003e\n\u003ctd\u003e~85% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany revenue\u003c\/td\u003e\n\u003ctd\u003e$372.6M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMolecular revenue growth\u003c\/td\u003e\n\u003ctd\u003e~18% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollab revenue\u003c\/td\u003e\n\u003ctd\u003e$58M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner sites\u003c\/td\u003e\n\u003ctd\u003e40+ (end-2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePer-test cost reduction\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics cost cut\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eVeracyte 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Veracyte 4P's Marketing Mix document you'll receive instantly after purchase-no surprises.\u003c\/p\u003e\n\u003cp\u003eYou're viewing the exact, fully complete analysis ready for download and immediate use; it's not a sample or demo.\u003c\/p\u003e\n\u003cp\u003eThis editable file is the final version included with your order, so buy with confidence and start applying the insights right away.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eromotion\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvidence-Based Marketing and Publications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte's promotion centers on publishing rigorous clinical validation studies in high-impact, peer-reviewed journals; 2024 filings cite \u0026gt;50 peer-reviewed publications supporting genomic tests such as Afirma and Percepta. By reporting sensitivity, specificity, and clinical utility-often with sensitivity \u0026gt;90% and specificity improvements of 20-30%-these papers build trust with clinicians and payers. The sales force uses publications as primary collateral when addressing skeptical physicians and hospital committees. This science-first strategy drove inclusion of Percepta in multiple guideline updates by 2023, boosting test adoption and reimbursement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePresence at Major Medical Congresses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte keeps a high profile at ASCO, ESMO, and AUA, sponsoring symposia, presenting data, and staffing interactive booths to engage KOLs and specialists.\u003c\/p\u003e\n\u003cp\u003eAt ASCO 2024 and AUA 2025 Veracyte showcased five pipeline studies and reported ~120 KOL meetings per year to drive adoption.\u003c\/p\u003e\n\u003cp\u003eThese congresses concentrate specialty audiences-often 20,000+ attendees-so visibility supports market share in molecular diagnostics and revenue growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Engagement and Professional Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte uses webinars, online case studies, and interactive diagnostic portals to educate clinicians on genomic medicine and its testing suite, reaching an estimated 120,000 HCPs globally in 2024 through 350+ events and resources.\u003c\/p\u003e\n\u003cp\u003eTargeted email campaigns and LinkedIn engagement drive clinician awareness and referrals, with digital channels accounting for roughly 45% of new test orders and a 22% higher conversion rate versus non-digital outreach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy and Awareness Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVeracyte partners with patient advocacy groups to raise genomic testing awareness, driving a patient-led pull where informed patients ask clinicians about tests; in 2024 Veracyte reported 23% revenue growth partly from increased test adoption.\u003c\/p\u003e\n\u003cp\u003ePrograms reduce diagnosis anxiety and emphasize avoiding unnecessary surgeries-Afirma and Percepta tests cut benign nodule surgeries by ~45% in peer studies-boosting outcomes and brand trust.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatient partnerships increase demand\u003c\/li\u003e\n\u003cli\u003e23% revenue growth in 2024\u003c\/li\u003e\n\u003cli\u003e~45% fewer unnecessary surgeries\u003c\/li\u003e\n\u003cli\u003eImproves brand and patient outcomes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Co-Marketing with Biopharma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVeracyte frequently co-markets with large-cap biopharma to educate physicians on how genomic signatures predict drug response, leveraging partners' broad sales forces and marketing budgets.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 these partnerships account for roughly 40% of Veracyte's commercial promotion of companion diagnostics, helping drive a 22% YoY increase in test orders in 2024-25.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCo-marketing focuses on physician education tied to genomic-drug links\u003c\/li\u003e\n\u003cli\u003ePartners provide scale-large-cap budgets and sales reach\u003c\/li\u003e\n\u003cli\u003e~40% of diagnostic promotion via partnerships by late 2025\u003c\/li\u003e\n\u003cli\u003e22% YoY rise in test orders across 2024-25\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScience‑led growth: Veracyte cuts surgeries ~45%, drives 23% revenue \u0026amp; 22% test growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte's promotion is science-first: \u0026gt;50 peer-reviewed studies (sensitivity \u0026gt;90%), 120K HCPs reached via 350+ events in 2024, 45% fewer benign surgeries, 23% revenue growth in 2024, digital = 45% of new orders, partnerships = ~40% of promotion by late 2025 driving 22% YoY test-order growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublications\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;50\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHCP reach 2024\u003c\/td\u003e\n\u003ctd\u003e120,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEvents\u003c\/td\u003e\n\u003ctd\u003e350+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBenign surgeries ↓\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue growth 2024\u003c\/td\u003e\n\u003ctd\u003e23%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital orders\u003c\/td\u003e\n\u003ctd\u003e45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartnership promo\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTest orders YoY\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003erice\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValue-Based Pricing Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte uses value-based pricing, setting test prices to capture savings from avoided surgeries and admissions-studies report reductions in unnecessary thyroid surgeries by ~45% and per-patient savings up to $2,500, supporting premiums ~20-30% above standard pathology by 2025.\u003c\/p\u003e\n\u003cp\u003eThis model leans on health economic evidence: payer analyses show payback within 6-18 months and ROI estimates of 2x-4x when long-term outcomes and survival gains from earlier, accurate diagnostics are included.\u003c\/p\u003e\n\u003cp\u003eMaintaining premiums requires continuous data: Veracyte publishes real-world evidence and cost-effectiveness models demonstrating QALY (quality-adjusted life year) gains and reduced downstream costs to justify reimbursement negotiations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare and Private Payer Reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePricing for Veracyte (NASDAQ: VCYT) hinges on CMS and private payer reimbursement; Medicare rates and insurer coverage drove about 68% of U.S. revenue in 2024, so CPT code assignments and national coverage decisions materially affect price realization. The company actively pursues favorable CPT codes and payer policies-Veracyte reported 95 payer contracts covering 180 million lives by Dec 31, 2024-to secure medically necessary determinations and sustainable reimbursement. Stable reimbursement supports Veracyte's gross margin (34% in FY2024) and predictable revenue guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePAMA and Regulatory Pricing Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte manages PAMA (Protecting Access to Medicare Act) pricing by reporting private-payer data so Medicare rates reflect market levels, reducing reimbursement risk; in 2024 median payment shifts under PAMA affected lab rates by ~8-12%. \u003c\/p\u003e\n\u003cp\u003eBy end-2025 Veracyte deployed automated reporting and pricing dashboards tied to payor mix, enabling quarterly adjustments and targeting a ±5% revenue variance vs. market benchmarks to avoid large cuts. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTiered Global Pricing Models\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVeracyte uses tiered global pricing to match local purchasing power, cutting nCounter kit list prices by 20-60% in lower-middle-income markets while keeping premium pricing in OECD countries to protect margins.\u003c\/p\u003e\n\u003cp\u003eThey also offer volume discounts and risk-sharing contracts with national health systems; a 2024 pilot in Brazil tied payments to outcomes and reduced net price by ~30% for a 2-year term.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003e20-60% price reductions in lower-income markets\u003c\/li\u003e\n\u003cli\u003e30% outcome-linked discounts (Brazil pilot, 2024)\u003c\/li\u003e\n\u003cli\u003eVolume discounts for national programs\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstitutional and Health System Contracting\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVeracyte contracts directly with large integrated health systems and academic medical centers, securing preferred-provider status and volume-based pricing that drives institution-wide adoption of its tests.\u003c\/p\u003e\n\u003cp\u003eThese agreements stabilize revenue and raise competitor entry costs; by late 2025 institutional partnerships account for roughly 40% of U.S. commercial test volume and about $160M of annual revenue.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePreferred-provider status across major systems\u003c\/li\u003e\n\u003cli\u003eVolume discounts tied to adoption rates\u003c\/li\u003e\n\u003cli\u003e~40% U.S. test volume from partners (late 2025)\u003c\/li\u003e\n\u003cli\u003e~$160M revenue contribution (annual, 2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte: 45% fewer surgeries, $2.5K savings, 2-4x payer ROI\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte prices tests on value: premiums ~20-30% above standard pathology justified by ~45% fewer unnecessary surgeries and up to $2,500 per-patient savings; payer ROI 2x-4x and payback 6-18 months. Medicare\/private reimbursement drove ~68% of U.S. revenue in 2024; 95 payer contracts covered 180M lives (Dec 31, 2024). Tiered global pricing cuts 20-60% in lower-income markets; institutional partnerships ~40% U.S. volume (~$160M, 2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnnecessary surgery reduction\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePer-patient savings\u003c\/td\u003e\n\u003ctd\u003eup to $2,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePremiums\u003c\/td\u003e\n\u003ctd\u003e20-30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 U.S. revenue from payers\u003c\/td\u003e\n\u003ctd\u003e~68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer contracts (2024)\u003c\/td\u003e\n\u003ctd\u003e95 (180M lives)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin FY2024\u003c\/td\u003e\n\u003ctd\u003e34%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional revenue (2025)\u003c\/td\u003e\n\u003ctd\u003e~$160M (40% volume)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Porter's Five Forces","offers":[{"title":"Default Title","offer_id":55640081006665,"sku":"veracyte-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0978\/1261\/1145\/files\/veracyte-marketing-mix.webp?v=1776738792","url":"https:\/\/five-forces.com\/products\/veracyte-marketing-mix","provider":"Porter’s Five Forces","version":"1.0","type":"link"}